McKinsey on risk : new risk challenges and enduring themes for the return
Contenido multimedia no disponible por derechos de autor o por acceso restringido. Contacte con la institución para más información.
| Tag | 1 | 2 | Valor |
|---|---|---|---|
| LDR | 00000cam a22000004b 4500 | ||
| 001 | MAP20210008153 | ||
| 003 | MAP | ||
| 005 | 20210315185250.0 | ||
| 008 | 180511e20210101usa|||| ||| ||eng d | ||
| 040 | $aMAP$bspa$dMAP | ||
| 084 | $a922.1 | ||
| 245 | 1 | 4 | $aMcKinsey on risk$b: new risk challenges and enduring themes for the return |
| 260 | $aNew York$bMcKinsey & Company$c2021 | ||
| 300 | $a116 p. | ||
| 520 | $aThe tenth issue of McKinsey on Risk arrives as spirits, battered by public-health and economic hardships, have been lifted by the appearance of COVID-19 vaccines. Vaccines are beginning to reach priority and vulnerable populations, such as healthcare workers and long-term care residents. Governments and institutions are promising ever-wider distribution in the months ahead. Serious questions remain about production timelines and the completeness of vaccine delivery. For most economies, epidemiological uncertainty is the main factor complicating the conditions of return. Yet nations, sectors, companies, and individuals have endured different challenges and will travel different recovery paths, depending on the damage done. | ||
| 650 | 4 | $0MAPA20080591182$aGerencia de riesgos | |
| 650 | 4 | $0MAPA20100017982$aRiesgos emergentes | |
| 650 | 4 | $0MAPA20080662257$aInterrupción de negocio | |
| 650 | 4 | $0MAPA20140016556$aResiliencia | |
| 650 | 4 | $0MAPA20080612429$aRiesgos extraordinarios | |
| 710 | 2 | $0MAPA20080442569$aMcKinsey & Company |